Director of Marketing and Communications
The Bonnie J. Addario Lung Cancer Foundation Honors Leading Lung Cancer Researcher with the 2016 Addario Lectureship Award
Giorgio Vittorio Scagliotti, M.D., honored at the 17th International Lung Cancer Congress
SAN CARLOS, Calif. (August 2, 2016) — The Bonnie J. Addario Lung Cancer Foundation (ALCF) will honor Giorgio Vittorio Scagliotti, M.D., Full Professor of Oncology at University of Torino and Head of the Department of Oncology and Chief of the Division of Medical Oncology at the San Luigi Hospital in Torino, Italy, with the 2016 Addario Lectureship Award for his continued leadership and expertise in the study of lung cancer, including malignant pleural mesothelioma. Dr. Scagliotti will receive the award at the 17th International Lung Cancer Congress held August 4-6 in Huntington Beach, California.
Dr. Scagliotti’s areas of research interest include: experimental studies on basic and clinical applied research on lung cancer, including translational research; molecular targeted therapies in lung cancer; and lung cancer chemotherapy, including investigators’ initiated studies.
“We are so pleased to present the Addario Lectureship Award this year to Dr. Scagliotti for his incredible leadership, research, and long-term dedication to the treatment of lung cancer,” said Bonnie J. Addario, 10-year lung cancer survivor and founder of the ALCF.
Each year the ALCF recognizes one special leader who is making great strides to eradicate lung cancer and fight for the lives affected by this disease. According to the American Cancer Society, more than 228,000 people in the United States will be diagnosed this year with lung cancer, and nearly 160,000 lung cancer patients will die. Cancer UK estimates that worldwide, nearly two million people are diagnosed with lung cancer each year.
Dr. Scagliotti earned his medical degree and completed postgraduate training in respiratory medicine, internal medicine, and medical oncology at the University of Torino. Dr. Scagliotti is a member of several scientific societies, including the Italian Society of Respiratory Medicine, The Italian Association of Medical Oncology, the European Respiratory Society, the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer.
From 2002 to 2005 he was member of the International Affair Committee of the American Society of Clinical Oncology and from 2003-2007 Executive Board member of the International Association for the Study of Lung Cancer. He is currently serving on the Publication Committee and he served in Program Committee of the American Society of Clinical Oncology in the period 2005-2007.
Dr. Scagliotti is a manuscript reviewer for several scientific journals. He currently serves on the editorial boards of Critical Review in Oncology and Hematology, and Oncology News. He is Associate Editor for Journal of Thoracic Oncology and International Editor for Clinical Lung Cancer. He is the author or co-author of more than 150 publications in peer-reviewed journals.
“Dr. Scagliotti’s work to bring together the international world of lung cancer research is inspiring to us all and we are so pleased to recognize and elevate his work through the Addario Lectureship Award,” said Addario.
Past Addario Lectureship Award recipients include:
“Giorgio Scagliotti is a modern day man for all seasons, a truly remarkable depth and breadth of expertise,” said Dr. Gandara, 2010 award recipient,
The ALCF has supported the Lung Cancer Congress for the past nine years and serves as a co-sponsor along with the IASLC. The annual three-day event provides physicians with practical information about the clinical implications of lung cancer screening, the latest clinical data impacting the treatment of lung cancer and novel agents and strategies that are changing the future of lung cancer therapy.
About the Bonnie J. Addario Lung Cancer Foundation The Bonnie J. Addario Lung Cancer Foundation (ALCF) is one of the largest international philanthropies (patient-founded, patient-focused and patient-driven) devoted exclusively to eradicating lung cancer through research, early detection, education and treatment. The Foundation’s goal is to work with a diverse group of physicians, organizations, industry partners, individuals, patients, survivors and their families to identify solutions and make timely and meaningful change and turn lung cancer into a chronically managed disease by 2023. The ALCF was established on March 1, 2006, as a 501c(3) non-profit organization and has raised more than $30 million for lung cancer research and related programs.